Associations - MET positive

BIOMARKER:

MET positive

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

MET positive MET positive	Solid Tumor Solid Tumor	GST-HG16 Sensitive: C2 – Inclusion Criteria GST-HG16 Sensitive : C2
MET positive MET positive	Squamous Cell Carcinoma of Head and Neck SCCHN	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
MET positive MET positive	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3
MET positive MET positive	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3